New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
06:10 EDTAKRXAkorn announces approval and launch of generic Prometrium
Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals has received approval of its abbreviated new drug application, or ANDA, for Progesterone capsules, 100mg and 200mg. The approved ANDA is for the generic of Abbott Laboratories' Prometrium capsules indicated for the treatment of endometrial hyperplasia and secondary amenorrhea. Akorn has exclusive marketing rights to Sofgen's product in the U.S. and the Company has begun distribution. According to IMS Health, Progesterone capsules, 100mg and 200mg, had combined sales of approximately $170M in the U.S. based on annualizing the three months ended August 31. IMS Health sales figures exclude certain customary discounts and incentives.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:51 EDTAKRXJefferies wonders if Akorn errors discovered by potential acquirer
Subscribe for More Information
07:14 EDTAKRXAkorn base business still well positioned, says JPMorgan
Subscribe for More Information
06:44 EDTAKRXAkorn downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
April 24, 2015
16:39 EDTAKRXAkorn down 10% after announcing additional financial restatements needed
Subscribe for More Information
16:16 EDTAKRXAkorn to resume trading at 4:35 pm ET
Subscribe for More Information
16:08 EDTAKRXAkorn backs FY15 adjusted EPS view $1.88-$1.98, consensus $1.95
16:07 EDTAKRXAkorn to make additional financial restatements
Subscribe for More Information
April 21, 2015
11:57 EDTAKRXAkorn rises, Perrigo slips after Teva makes long-rumored Mylan bid
The shares of drugmaker Akorn (AKRX) are rising after Israeli pharmaceutical company Teva (TEVA) earlier today made a takeover bid for another company in the space, generic drugmaker Mylan (MYL). WHAT'S NEW: Teva announced an $82 per share takeover bid for generic drug maker Mylan earlier today. The latter company said that Teva's takeover offer is a more attractive option for it than acquiring another generic drug maker, Perrigo (PRGO). On April 8, Mylan made a $205 per share takeover offer for Perrigo. Teva's bid comes less than a week after Mylan Chairman Robert Coury said that rumors of potential interest from Teva had been "circulating for some time," but that such a combination was "without sound industrial logic or cultural fit" and would be unlikely to receive antitrust regulatory clearances. ANALYST OPINION: In a note to investors on April 15, RBC Capital analyst Randall Stanicky wrote that Perrigo may have been engaging other companies in talks after Mylan came public with its takeover offer. Stanicky said he saw no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. The analyst added that Acorn is well-positioned as a derivative takeover target following Mylan's offer for Perrigo, noting Acorn's strong growth and high tax rate. In a note to investors yesterday, Citigroup said it believed a potential takeover of Mylan by Teva would have to be friendly after its legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. Citi estimated an $80 per share bid for Mylan would be 25%-35% accretive from 2016 onward for Teva while a $90 per share bid would be 20%-30% accretive. The firm added that it believes it is likely that Mylan received resistance from shareholders since the announcement of its proposed acquisition of Perrigo. PRICE ACTION: In late morning trading, Akorn rose 2.2% to $55.85, Perrigo dropped 2.4% to $193.24, Mylan jumped 9.3% to $74.39, and Teva rose 2.1% to $64.64.
April 15, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTAKRXRBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
08:19 EDTAKRXAkorn management to meet with Deutsche Bank
Subscribe for More Information
06:24 EDTAKRXAkorn initiated with an Overweight, $61 target at JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use